Is Achieve Life Sciences, Inc. (ACHV) a Buy, Sell, or Hold?
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$6.31 USD
$0.21 (3.44%)
- Volume
- 1.63M
- Average Volume
- 2.09M
- Market Capitalization
- $647.78M
- P/E Ratio
- -5.63
- Dividend Yield
- 0.00%
- Price Target
- $16.50
- Year High
- $7.11
- Year Low
- $2.37
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.62
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard A. Stewart |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACHV |
| CUSIP | 004468500 |
| CIK | 0000949858 |
| Web | https://www.achievelifesciences.com |
| Phone | 14256861500 |
| Currency | USD |
| Employees | 28 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.40 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.62 |
| Quick Ratio | 2.62 |
| Cash Ratio | 2.37 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.85 |
| Price / Cash Flow | -14.30 |
| Price / Book | 31.55 |
Price Target and Rating
| Average Stock Price Forecast | $16.50 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -61.76% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.25 |
| Trailing P/E Ratio | -5.63 |
| PEG Ratio | -0.36 |
| P/E Growth | -0.36 |
| Net Income | $-54.65M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -193.49% |
| Return on Assets | -157.04% |
Financials Score
| AltmanZ Score | 0.92 |
| Piotroski Score | 1.00 |
| Working Capital | 19.23M |
| Total Assets | 33.1M |
| Ebit | -51.08M |
| Market Cap | 626.22M |
| Total Liabilities | 22.43M |
Poll Results
About Achieve Life Sciences, Inc. (NASDAQ:ACHV) Stock
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada. ...
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
2026-07-09 20:03:12
Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company's Chief Legal Officer, would act as secretary and record the minutes.
Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able
2026-07-07 11:33:38
The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now, thanks to successful financing, progress on shifting its supply chain, and new leadership. Despite the CRL, ACHV continues to advance. The denial was not drug-related, pointing towards a possible successful outcome in this story.
Achieve Life Sciences Joins Russell 2000® Index
2026-06-29 08:30:00
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index.
Achieve Life Sciences: CRL Is Fixable, So I Remain Bullish
2026-06-23 07:30:14
Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping. The FDA's CRL appears to be mostly about manufacturing and labeling issues. However, it's not about a particular cytisinicline efficacy or safety problem. ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned
2026-06-22 11:44:44
Achieve Life Sciences Inc. (NASDAQ:ACHV) on Monday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application seeking approval of cytisinicline, its investigational treatment for nicotine dependence.
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
2026-06-22 08:54:18
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, the company said on Monday.
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
2026-06-22 08:30:00
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for cytisinicline. The CRL relates to outstanding manufacturing-related observations from a current Good Manufacturing Practice (cGMP) inspection of a third-party manufacturing facility and to final product labeling that was not completed by the FDA's action date.
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
2026-06-02 08:30:00
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch
Frequently Asked Questions
-
What is the current Achieve Life Sciences, Inc. (ACHV) stock price?
-
Achieve Life Sciences, Inc.(NASDAQ:ACHV) stock price is $6.31 in the last trading session. During the trading session, ACHV stock reached the peak price of $7.11 while $2.37 was the lowest point it dropped to. The percentage change in ACHV stock occurred in the recent session was 3.44% while the dollar amount for the price change in ACHV stock was $0.21.
-
ACHV's industry and sector of operation?
-
The NASDAQ listed ACHV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACHV?
-
Andrew D. Goldberg | CEO, President & Director
Mark L. Rubinstein | Chief Medical Officer
Craig Donnelly | Chief Operations Officer
Erik Atkisson | Chief Legal Officer
Jerry Wan | Vice President of Finance & Principal Accounting Officer -
How many employees does ACHV have?
-
Number of ACHV employees currently stands at 28. ACHV operates from 22722 29th Dr. SE, Bothell, BC 98021, US.
-
Link for ACHV official website?
-
Official Website of ACHV is: https://www.achievelifesciences.com
-
How do I contact ACHV?
-
ACHV could be contacted at phone #14256861500 and can also be accessed through its website. ACHV operates from 22722 29th Dr. SE, Bothell, BC 98021, US.
-
How many shares of ACHV are traded daily?
-
The average number of ACHV shares traded daily for last 3 months was 2.09M.
-
What is the market cap of ACHV currently?
-
The market value of ACHV currently stands at $647.78M with its latest stock price at $6.31